S&P 500   4,285.49 (-1.20%)
DOW   33,677.71 (-0.97%)
QQQ   355.24 (-1.22%)
AAPL   172.93 (-1.79%)
MSFT   311.94 (-1.76%)
META   298.70 (-0.71%)
GOOGL   127.68 (-2.62%)
AMZN   127.27 (-3.05%)
TSLA   247.87 (+0.36%)
NVDA   422.79 (+0.14%)
NIO   8.55 (+2.40%)
BABA   86.28 (-1.08%)
AMD   96.06 (-1.36%)
T   14.99 (-0.46%)
F   12.53 (-0.40%)
MU   68.21 (-0.54%)
CGC   0.95 (+1.04%)
GE   109.87 (-1.66%)
DIS   80.37 (-0.79%)
AMC   8.27 (+1.60%)
PFE   32.75 (-0.70%)
PYPL   58.87 (+0.02%)
NFLX   382.82 (-0.51%)
S&P 500   4,285.49 (-1.20%)
DOW   33,677.71 (-0.97%)
QQQ   355.24 (-1.22%)
AAPL   172.93 (-1.79%)
MSFT   311.94 (-1.76%)
META   298.70 (-0.71%)
GOOGL   127.68 (-2.62%)
AMZN   127.27 (-3.05%)
TSLA   247.87 (+0.36%)
NVDA   422.79 (+0.14%)
NIO   8.55 (+2.40%)
BABA   86.28 (-1.08%)
AMD   96.06 (-1.36%)
T   14.99 (-0.46%)
F   12.53 (-0.40%)
MU   68.21 (-0.54%)
CGC   0.95 (+1.04%)
GE   109.87 (-1.66%)
DIS   80.37 (-0.79%)
AMC   8.27 (+1.60%)
PFE   32.75 (-0.70%)
PYPL   58.87 (+0.02%)
NFLX   382.82 (-0.51%)
S&P 500   4,285.49 (-1.20%)
DOW   33,677.71 (-0.97%)
QQQ   355.24 (-1.22%)
AAPL   172.93 (-1.79%)
MSFT   311.94 (-1.76%)
META   298.70 (-0.71%)
GOOGL   127.68 (-2.62%)
AMZN   127.27 (-3.05%)
TSLA   247.87 (+0.36%)
NVDA   422.79 (+0.14%)
NIO   8.55 (+2.40%)
BABA   86.28 (-1.08%)
AMD   96.06 (-1.36%)
T   14.99 (-0.46%)
F   12.53 (-0.40%)
MU   68.21 (-0.54%)
CGC   0.95 (+1.04%)
GE   109.87 (-1.66%)
DIS   80.37 (-0.79%)
AMC   8.27 (+1.60%)
PFE   32.75 (-0.70%)
PYPL   58.87 (+0.02%)
NFLX   382.82 (-0.51%)
S&P 500   4,285.49 (-1.20%)
DOW   33,677.71 (-0.97%)
QQQ   355.24 (-1.22%)
AAPL   172.93 (-1.79%)
MSFT   311.94 (-1.76%)
META   298.70 (-0.71%)
GOOGL   127.68 (-2.62%)
AMZN   127.27 (-3.05%)
TSLA   247.87 (+0.36%)
NVDA   422.79 (+0.14%)
NIO   8.55 (+2.40%)
BABA   86.28 (-1.08%)
AMD   96.06 (-1.36%)
T   14.99 (-0.46%)
F   12.53 (-0.40%)
MU   68.21 (-0.54%)
CGC   0.95 (+1.04%)
GE   109.87 (-1.66%)
DIS   80.37 (-0.79%)
AMC   8.27 (+1.60%)
PFE   32.75 (-0.70%)
PYPL   58.87 (+0.02%)
NFLX   382.82 (-0.51%)
NASDAQ:SOPH

SOPHiA GENETICS (SOPH) Stock Forecast, Price & News

$2.44
+0.03 (+1.24%)
(As of 11:31 AM ET)
Compare
Today's Range
$2.41
$2.52
50-Day Range
$2.30
$4.27
52-Week Range
$1.68
$5.77
Volume
1,664 shs
Average Volume
84,560 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.33

SOPHiA GENETICS MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
153.3% Upside
$6.33 Price Target
Short Interest
Healthy
0.06% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of SOPHiA GENETICS in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.20) to ($0.88) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.72 out of 5 stars


SOPH stock logo

About SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS SA operates as a cloud-native software technology company in the healthcare space. The company offers SOPHiA DDM platform, a cloud-native software platform for analyzing data and generating insights from multimodal data sets and diagnostic modalities. Its SOPHiA DDM platform and related solutions, applications, products, and services are used by hospitals, laboratories, and biopharma customers worldwide. The company was incorporated in 2011 and is headquartered in Saint-Sulpice, Switzerland.

SOPH Price History

SOPH Stock News Headlines

SOPHiA GENETICS (NASDAQ:SOPH) Stock Price Up 5%
Bringing Space Down to Earth
Cutting edge, AI-powered, Space-based Earth-observation solutions
Laboratorio Curie Expands Relationship with SOPHiA GENETICS
CHU Bordeaux is live on SOPHiA GENETICS
Laser breakthrough could send stock soaring 2,467%
Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...
SOPHiA Genetics (NASDAQ: SOPH)
J.P. Morgan Remains a Buy on SOPHiA GENETICS (SOPH)
A Preview Of Sophia Genetics's Earnings
SOPHiA GENETICS SA earnings preview: what Wall Street is expecting
See More Headlines
Receive SOPH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for SOPHiA GENETICS and its competitors with MarketBeat's FREE daily newsletter.

SOPH Company Calendar

Last Earnings
8/08/2023
Today
9/26/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SOPH
Fax
N/A
Employees
466
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.33
High Stock Price Forecast
$11.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+153.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-87,450,000.00
Net Margins
-145.00%
Pretax Margin
-145.34%

Debt

Sales & Book Value

Annual Sales
$47.56 million
Book Value
$3.16 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
1.33
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Jurgi Camblong M.B.A. (Age 45)
    Ph.D., Co-Founder, CEO & Director
    Comp: $1.11M
  • Mr. Ross Jordan Muken B.Sc. (Age 42)
    Exec. VP, CFO & COO
  • Mr. Abhimanyu Verma
    Sr. VP & CTO
  • Dr. Zhenyu Xu Ph.D. (Age 40)
    Exec. VP & Chief Scientific Officer
  • Katherine Bailon
    VP of Investor Relations
  • Mr. Daan van Well L.L.M. (Age 49)
    M.B.A., Exec. VP, Chief Legal Officer & Gen. Counsel
  • Mr. Kevin Puylaert
    VP of Bus. Devel. & Marketing
  • Ms. Manuela Da Silva Valente B.A. (Age 52)
    Sr. VP & Chief People Officer
  • Dr. Philippe Menu M.B.A. (Age 41)
    M.D., Ph.D., Exec. VP, Chief Medical Officer & Chief Product Officer
  • Mr. Peter Casasanto
    Sr. VP & Chief BioPharma Officer













SOPH Stock - Frequently Asked Questions

Should I buy or sell SOPHiA GENETICS stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SOPHiA GENETICS in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" SOPH shares.
View SOPH analyst ratings
or view top-rated stocks.

What is SOPHiA GENETICS's stock price forecast for 2023?

3 brokers have issued twelve-month target prices for SOPHiA GENETICS's shares. Their SOPH share price forecasts range from $2.00 to $11.00. On average, they expect the company's stock price to reach $6.33 in the next twelve months. This suggests a possible upside of 153.3% from the stock's current price.
View analysts price targets for SOPH
or view top-rated stocks among Wall Street analysts.

How have SOPH shares performed in 2023?

SOPHiA GENETICS's stock was trading at $2.06 at the beginning of the year. Since then, SOPH shares have increased by 21.4% and is now trading at $2.50.
View the best growth stocks for 2023 here
.

When is SOPHiA GENETICS's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our SOPH earnings forecast
.

How were SOPHiA GENETICS's earnings last quarter?

SOPHiA GENETICS SA (NASDAQ:SOPH) released its quarterly earnings results on Tuesday, August, 8th. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.29) by $0.04. The company earned $15.05 million during the quarter, compared to analysts' expectations of $15.10 million. SOPHiA GENETICS had a negative trailing twelve-month return on equity of 41.11% and a negative net margin of 145.00%.

What guidance has SOPHiA GENETICS issued on next quarter's earnings?

SOPHiA GENETICS updated its FY 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $61.83M-, compared to the consensus revenue estimate of $62.12 million.

When did SOPHiA GENETICS IPO?

(SOPH) raised $234 million in an IPO on Friday, July 23rd 2021. The company issued 13,000,000 shares at $17.00-$19.00 per share.

What is SOPHiA GENETICS's stock symbol?

SOPHiA GENETICS trades on the NASDAQ under the ticker symbol "SOPH."

Who are SOPHiA GENETICS's major shareholders?

SOPHiA GENETICS's stock is owned by many different retail and institutional investors. Top institutional shareholders include Credit Suisse AG (0.00%), Principal Financial Group Inc. (0.00%), Pura Vida Investments LLC (0.00%), Geode Capital Management LLC (0.00%), JPMorgan Chase & Co. (0.00%) and Meitav Investment House Ltd. (0.04%).

How do I buy shares of SOPHiA GENETICS?

Shares of SOPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SOPHiA GENETICS's stock price today?

One share of SOPH stock can currently be purchased for approximately $2.50.

How many employees does SOPHiA GENETICS have?

The company employs 466 workers across the globe.

How can I contact SOPHiA GENETICS?

The official website for the company is www.sophiagenetics.com. The company can be reached via phone at 41-21-694-1060.

This page (NASDAQ:SOPH) was last updated on 9/26/2023 by MarketBeat.com Staff

My Account -